Abstract
To develop drugs to kill cancer cells, we chemically synthesized a number of anti-cancer agents by adding different side chains to the core backbone of saponin. With the use of bioassay-guided methods, we found one agent that possessed a high cytotoxicity to a number of cancer cell lines. Interestingly, this compound was later found to be an active component of a tradition Chinese herb Paris polyphylla known as Polyphyllin D (PD) (diosgenyl α-L-rhamnopyranosyl- (1→2)-(β-L-ara-binofuranosyl-(1→4)-β-D-glucopyranoside). In China, the rhizome of Paris polyphylla (Chong Lou) has been used as a traditional Chinese medicine to treat a number of cancers including pancreas and liver cancers for a long time. Results from our laboratory demonstrate that PD is a potent anti-cancer agent that bypasses multi-drug resistance (MDR) and induces programmed cell death in R-HepG2 cells over-expressing P-glycoprotein (P-gp). In this paper, we reviewed the mechanisms how PD overcomes the MDR and exhibits a stronger cytotoxicity in the R-HepG2 than its parent line without P-gp through mitochondrial injury.
Keywords: Polyphyllin D, apoptosis, multi-drug resistance, mitochondria, R-HepG2
Current Chemical Biology
Title: Polyphyllin D - A Potential Anti-Cancer Agent to Kill Hepatocarcinoma Cells with Multi-Drug Resistance
Volume: 3 Issue: 1
Author(s): Tim T. Kwok, Siu K. Kong, Ming Li, Ho P. Ho, Bao Yu, Kwok P. Fung, Yick K. Suen, Judy Y.W. Chan, Macey M.S. Lee, Yan C. Li, Rebecca K.Y. Lee, Rose C.Y. Ong and Jenny Y.N. Cheung
Affiliation:
Keywords: Polyphyllin D, apoptosis, multi-drug resistance, mitochondria, R-HepG2
Abstract: To develop drugs to kill cancer cells, we chemically synthesized a number of anti-cancer agents by adding different side chains to the core backbone of saponin. With the use of bioassay-guided methods, we found one agent that possessed a high cytotoxicity to a number of cancer cell lines. Interestingly, this compound was later found to be an active component of a tradition Chinese herb Paris polyphylla known as Polyphyllin D (PD) (diosgenyl α-L-rhamnopyranosyl- (1→2)-(β-L-ara-binofuranosyl-(1→4)-β-D-glucopyranoside). In China, the rhizome of Paris polyphylla (Chong Lou) has been used as a traditional Chinese medicine to treat a number of cancers including pancreas and liver cancers for a long time. Results from our laboratory demonstrate that PD is a potent anti-cancer agent that bypasses multi-drug resistance (MDR) and induces programmed cell death in R-HepG2 cells over-expressing P-glycoprotein (P-gp). In this paper, we reviewed the mechanisms how PD overcomes the MDR and exhibits a stronger cytotoxicity in the R-HepG2 than its parent line without P-gp through mitochondrial injury.
Export Options
About this article
Cite this article as:
Kwok T. Tim, Kong K. Siu, Li Ming, Ho P. Ho, Yu Bao, Fung P. Kwok, Suen K. Yick, Chan Y.W. Judy, Lee M.S. Macey, Li C. Yan, Lee K.Y. Rebecca, Ong C.Y. Rose and Cheung Y.N. Jenny, Polyphyllin D - A Potential Anti-Cancer Agent to Kill Hepatocarcinoma Cells with Multi-Drug Resistance, Current Chemical Biology 2009; 3 (1) . https://dx.doi.org/10.2174/2212796810903010089
DOI https://dx.doi.org/10.2174/2212796810903010089 |
Print ISSN 2212-7968 |
Publisher Name Bentham Science Publisher |
Online ISSN 1872-3136 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Ribosomal Proteins and Colorectal Cancer
Current Genomics Applications of Mesoporous Materials as Excipients for Innovative Drug Delivery and Formulation
Current Pharmaceutical Design The Application of Nanotechnological Therapeutic Platforms against Gynecological Cancers
Current Pharmaceutical Design Peptide Activators of the p53 Tumor Suppressor
Current Pharmaceutical Design Advancement and Strategies for the Development of Peptide-drug Conjugates: Pharmacokinetic Modulation, Role and Clinical Evidence against Cancer Management
Current Cancer Drug Targets Cancer Gene Therapy with Tissue Inhibitors of Metalloproteinases (TIMPs)
Current Gene Therapy Patents on Immunotoxins and Chimeric Toxins for the Treatment of Cancer
Recent Patents on Drug Delivery & Formulation Anti-Cancer Agent-Induced Nephrotoxicity
Anti-Cancer Agents in Medicinal Chemistry Doxorubicin: The Good, the Bad and the Ugly Effect
Current Medicinal Chemistry Substrate Spectra of Nucleoside Phosphorylases and their Potential in the Production of Pharmaceutically Active Compounds
Current Pharmaceutical Design The Novel Role for Lyn in Integrin Signaling in Human Disease
Current Signal Transduction Therapy Biochemical and Preclinical Evaluation with Synthesis and Docking Study of Pyridopyrimidines and Selenium Nanoparticle Drugs for Cancer Targeting
Current Nanoscience Xenobiotic-Induced Transcriptional Regulation of Xenobiotic Metabolizing Enzymes of the Cytochrome P450 Superfamily in Human Extrahepatic Tissues
Current Drug Metabolism Recent Updates on Biological Activities of Oxadiazoles
Mini-Reviews in Medicinal Chemistry Advances in Photodynamic Therapy of Cancer
Current Cancer Therapy Reviews Hypothesizing the Green Synthesis of Tamoxifen Loaded Magnetic Nanoparticles for the Treatment of Breast Cancer
Current Molecular Medicine MicroRNA Expression in Coronary Artery Disease
MicroRNA Application of Serial Analysis of Gene Expression in Cancer Research
Current Pharmaceutical Biotechnology Gut Microbiota Modulation and Mucosal Immunity: Focus on Rifaximin
Mini-Reviews in Medicinal Chemistry Synthesis, Antioxidant and Antitumor Activity of Some Substituted 9-Anilinoacridine and 4-Anilinoquinolines Derivatives
Current Organic Synthesis